| NCT Number | NCT07186621 |
| Lead Sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Collaborators: Peking University People's Hospital, Nanfang Hospital, Southern Medical University, Beijing 302 Hospital, Beijing Ditan Hospital, Eastern Hepatobiliary Surgery Hospital |
| Conditions | Hepatocellular Carcinoma (HCC), Radiotherapy, Adjuvant, Immune Checkpoint Inhibitor, TACE, Narrow Margin |
| Enrollment | 286 participants |
| Start Date | 2025-07-10 |
| Primary Completion | 2027-07-09 (estimated) |
| Study Completion | 2028-11-30 (estimated) |
| Updated on ClinicalTrials.gov | 2025-09-22 |